Seeking Alpha

Zogenix (ZGNX +44%) continues to surge higher this morning on the news of the FDA decision to...

Zogenix (ZGNX +44%) continues to surge higher this morning on the news of the FDA decision to push back its PDUFA date for Zohydro. Analysts see the delay as a potential positive, as it's likely to be short-lived and the odds for eventual approval are still high. Wells Fargo's Michael Tong sees just 20% downside on a negative FDA decision but potentially 100%+ upside for the stock if given the green light.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|